Should I buy or sell eFFECTOR Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EFTR shares. View EFTR analyst ratings or view top-rated stocks .

What is eFFECTOR Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 12-month price targets for eFFECTOR Therapeutics' shares. Their EFTR share price targets range from $24.00 to $24.00. On average, they anticipate the company's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 1,311.8% from the stock's current price. View analysts price targets for EFTR or view top-rated stocks among Wall Street analysts .

How have EFTR shares performed in 2024?

eFFECTOR Therapeutics' stock was trading at $11.6850 at the beginning of 2024. Since then, EFTR stock has decreased by 85.5% and is now trading at $1.70. View the best growth stocks for 2024 here .

Are investors shorting eFFECTOR Therapeutics?

eFFECTOR Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 345,200 shares, an increase of 8.5% from the March 15th total of 318,100 shares. Based on an average daily trading volume, of 358,000 shares, the short-interest ratio is currently 1.0 days. Currently, 10.7% of the company's stock are short sold. View eFFECTOR Therapeutics' Short Interest .

When is eFFECTOR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EFTR earnings forecast .

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) posted its quarterly earnings data on Monday, March, 25th. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($2.73) by $0.69.

When did eFFECTOR Therapeutics' stock split?

eFFECTOR Therapeutics shares reverse split on the morning of Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EFTR

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EFTR Stock Alerts

$1.70

-0.08 (-4.49%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.60
▼
$1.80
50-Day Range: $1.70
▼
$16.95
52-Week Range: $1.60
▼
$37.00

Volume: 197,040 shs
Average Volume: 335,958 shs
Market Capitalization: $6.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.00

Get eFFECTOR Therapeutics alerts:

eFFECTOR Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,311.8% Upside
$24.00 Price Target
Short Interest: Bearish
10.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.18) to ($2.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.20 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
eFFECTOR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
eFFECTOR Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
10.72% of the float of eFFECTOR Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
eFFECTOR Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in eFFECTOR Therapeutics has recently increased by 8.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
eFFECTOR Therapeutics does not currently pay a dividend.
Dividend Growth
eFFECTOR Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EFTR.

1.1

News and Social Media Coverage

Search Interest
18 people have searched for EFTR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
5 people have added eFFECTOR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.40% of the stock of eFFECTOR Therapeutics is held by insiders.
Percentage Held by Institutions
57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for eFFECTOR Therapeutics are expected to grow in the coming year, from ($5.18) to ($2.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of eFFECTOR Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of eFFECTOR Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

EFTR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EFTR Stock News Headlines

April 9, 2024 | globenewswire.com

eFFECTOR Therapeutics to Participate in Upcoming Investor Conference

April 4, 2024 | marketwatch.com

EFFECTOR Therapeutics Shares Drop as Development of Lung Cancer Treatment Drug Ends

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 4, 2024 | markets.businessinsider.com

EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC

April 4, 2024 | finance.yahoo.com

Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

April 4, 2024 | globenewswire.com

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

March 28, 2024 | markets.businessinsider.com

Buy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin Trials

March 27, 2024 | finanznachrichten.de

eFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | investorplace.com

EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023

March 25, 2024 | globenewswire.com

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 19, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)

February 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for eFFECTOR Therapeutics Amid Promising Oncology Drug Milestones and Extended Financial Runway

January 31, 2024 | msn.com

eFFECTOR Therapeutics Regains Nasdaq Compliance Status

January 30, 2024 | finance.yahoo.com

Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?

January 25, 2024 | finance.yahoo.com

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 10, 2024 | finanznachrichten.de

eFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Announces Reverse Stock Split

January 9, 2024 | msn.com

eFFECTOR Therapeutics announces 1-for-25 reverse stock split

December 8, 2023 | msn.com

eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study

December 8, 2023 | finance.yahoo.com

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

November 28, 2023 | msn.com

eFFECTOR stock rises after FDA fast track status for breast cancer therapy

November 17, 2023 | markets.businessinsider.com

Buy Rating for eFFECTOR Therapeutics Based on Promising Drug Developments and Capital Security

November 13, 2023 | msn.com

eFFECTOR Therapeutics GAAP EPS of -$0.13 misses by $0.01

November 13, 2023 | tmcnet.com

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

September 20, 2023 | fool.com

eFFECTOR Therapeutics (NASDAQ: EFTR)

August 25, 2023 | msn.com

HC Wainwright starts eFFECTOR at buy, cites drug technology platform

August 24, 2023 | nasdaq.com

HC Wainwright & Co. Initiates Coverage of eFFECTOR Therapeutics (EFTR) with Buy Recommendation

See More Headlines

Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EFTR
CUSIP: N/A
CIK: 1828522
Web: www.locustwalkacquisitioncorp.com
Phone: 858-925-8215
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $24.00
High Stock Price Target: $24.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +1,337.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($16.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,810,000.00
Net Margins: N/A
Pretax Margin: -5,332.49%
Return on Equity: N/A
Return on Assets: -160.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.77
Quick Ratio: 0.77

Sales & Book Value

Annual Sales: $3.55 million
Price / Sales: 1.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.94) per share
Price / Book: -0.86

Miscellaneous

Outstanding Shares: 3,690,000
Free Float: 3,377,000
Market Cap: $6.16 million
Optionable: Optionable
Beta: 0.52

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Stephen T. Worland Ph.D. (Age 66)
CEO, President & Director
Comp: $873.96k
Mr. Michael Byrnes M.B.A. (Age 47)
Chief Financial Officer
Comp: $654.82k
Dr. Douglas Warner M.D. (Age 52)
Chief Medical Officer
Comp: $660.16k
Dr. Davide Ruggero Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EFTR Stock Analysis - Frequently Asked Questions

Should I buy or sell eFFECTOR Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EFTR shares.
View EFTR analyst ratings or view top-rated stocks.
What is eFFECTOR Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued 12-month price targets for eFFECTOR Therapeutics' shares. Their EFTR share price targets range from $24.00 to $24.00. On average, they anticipate the company's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 1,311.8% from the stock's current price.
View analysts price targets for EFTR or view top-rated stocks among Wall Street analysts.
How have EFTR shares performed in 2024?: eFFECTOR Therapeutics' stock was trading at $11.6850 at the beginning of 2024. Since then, EFTR stock has decreased by 85.5% and is now trading at $1.70.
View the best growth stocks for 2024 here.
Are investors shorting eFFECTOR Therapeutics?: eFFECTOR Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 345,200 shares, an increase of 8.5% from the March 15th total of 318,100 shares. Based on an average daily trading volume, of 358,000 shares, the short-interest ratio is currently 1.0 days. Currently, 10.7% of the company's stock are short sold.
View eFFECTOR Therapeutics' Short Interest.

When is eFFECTOR Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EFTR earnings forecast.
How were eFFECTOR Therapeutics' earnings last quarter?: eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) posted its quarterly earnings data on Monday, March, 25th. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($2.73) by $0.69.
When did eFFECTOR Therapeutics' stock split?: eFFECTOR Therapeutics shares reverse split on the morning of Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
How do I buy shares of eFFECTOR Therapeutics?: Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EFTR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

eFFECTOR Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)

EFTR Stock Price History

EFTR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EFTR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™